Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Brief Summary
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.
| Primary Purpose | Study Type | Phase |
|---|---|---|
| Treatment | Interventional | Phase IV |
Eligibility
| Gender | Healthy Volunteers |
|---|---|
| All | No |
| Minimum Age | Maximum Age |
|---|---|
| 13 Years | N/A |
Related Posts
Brief Summary The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous[...]
Brief Summary The purpose of the research is to evaluate the feasibility and scalability of delivering a 30-minute novel virtual reality (VR) experience through the[...]